CA2437250A1 - Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente - Google Patents

Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente Download PDF

Info

Publication number: CA2437250A1
Authority: CA; Canada
Prior art keywords: alginate; cells; islet; islets; des
Prior art date: 2003-08-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2437250

Other languages

English (en)

Inventor

Francois Leblond

Guillaume Jourdan

Jean-Pierre Halle

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

IMS RECH Inc

Original Assignee

IMS RECHERCHE Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-14

Filing date

2003-08-14

Publication date

2005-02-14

2003-08-14 Application filed by IMS RECHERCHE Inc filed Critical IMS RECHERCHE Inc

2003-08-14 Priority to CA 2437250 priority Critical patent/CA2437250A1/fr

2005-02-14 Publication of CA2437250A1 publication Critical patent/CA2437250A1/fr

Status Abandoned legal-status Critical Current

Links

229940072056 alginate Drugs 0.000 title abstract description 37
229920000615 alginic acid Polymers 0.000 title abstract description 37
239000012528 membrane Substances 0.000 title abstract description 13
210000004027 cell Anatomy 0.000 abstract description 163
210000004153 islets of langerhan Anatomy 0.000 abstract description 66
238000000034 method Methods 0.000 abstract description 63
230000000694 effects Effects 0.000 abstract description 48
239000003094 microcapsule Substances 0.000 abstract description 35
238000002054 transplantation Methods 0.000 abstract description 35
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract description 34
230000004083 survival effect Effects 0.000 abstract description 34
235000010443 alginic acid Nutrition 0.000 abstract description 33
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 30
238000006243 chemical reaction Methods 0.000 abstract description 22
229920000729 poly(L-lysine) polymer Polymers 0.000 abstract description 16
102000004877 Insulin Human genes 0.000 abstract description 15
108090001061 Insulin Proteins 0.000 abstract description 15
238000011534 incubation Methods 0.000 abstract description 15
229940125396 insulin Drugs 0.000 abstract description 15
239000004472 Lysine Substances 0.000 abstract description 14
239000002775 capsule Substances 0.000 abstract description 12
238000013459 approach Methods 0.000 abstract description 11
239000011324 bead Substances 0.000 abstract description 10
230000002035 prolonged effect Effects 0.000 abstract description 9
241000282414 Homo sapiens Species 0.000 abstract description 8
238000002474 experimental method Methods 0.000 abstract description 8
210000000130 stem cell Anatomy 0.000 abstract description 8
241000700605 Viruses Species 0.000 abstract description 7
238000002360 preparation method Methods 0.000 abstract description 7
230000010076 replication Effects 0.000 abstract description 7
239000000126 substance Substances 0.000 abstract description 7
108700023471 alginate-polylysine-alginate Proteins 0.000 abstract description 6
230000007774 longterm Effects 0.000 abstract description 6
230000035699 permeability Effects 0.000 abstract description 6
239000000243 solution Substances 0.000 abstract description 6
230000004913 activation Effects 0.000 abstract description 5
238000000338 in vitro Methods 0.000 abstract description 5
206010064912 Malignant transformation Diseases 0.000 abstract description 4
230000015572 biosynthetic process Effects 0.000 abstract description 4
230000006378 damage Effects 0.000 abstract description 4
230000036212 malign transformation Effects 0.000 abstract description 4
230000008569 process Effects 0.000 abstract description 4
239000004971 Cross linker Substances 0.000 abstract description 3
239000011248 coating agent Substances 0.000 abstract description 3
230000006872 improvement Effects 0.000 abstract description 3
230000003993 interaction Effects 0.000 abstract description 3
AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 abstract description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 2
230000001363 autoimmune Effects 0.000 abstract description 2
AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 abstract description 2
230000003833 cell viability Effects 0.000 abstract description 2
238000004132 cross linking Methods 0.000 abstract description 2
238000009795 derivation Methods 0.000 abstract description 2
CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical group [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 abstract description 2
FUOJEDZPVVDXHI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-azido-2-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC=C(N=[N+]=[N-])C=C1C(=O)ON1C(=O)CCC1=O FUOJEDZPVVDXHI-UHFFFAOYSA-N 0.000 abstract 2
239000012670 alkaline solution Substances 0.000 abstract 2
230000015556 catabolic process Effects 0.000 abstract 2
238000006731 degradation reaction Methods 0.000 abstract 2
238000005286 illumination Methods 0.000 abstract 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 abstract 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 abstract 1
229910052791 calcium Inorganic materials 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
235000010410 calcium alginate Nutrition 0.000 abstract 1
229960002681 calcium alginate Drugs 0.000 abstract 1
239000000648 calcium alginate Substances 0.000 abstract 1
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
238000010668 complexation reaction Methods 0.000 abstract 1
238000006073 displacement reaction Methods 0.000 abstract 1
230000009881 electrostatic interaction Effects 0.000 abstract 1
210000001671 embryonic stem cell Anatomy 0.000 abstract 1
230000007935 neutral effect Effects 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
229920002851 polycationic polymer Polymers 0.000 abstract 1
230000000750 progressive effect Effects 0.000 abstract 1
241000700159 Rattus Species 0.000 description 88
108090000623 proteins and genes Proteins 0.000 description 62
206010012601 diabetes mellitus Diseases 0.000 description 51
230000014509 gene expression Effects 0.000 description 37
241000699670 Mus sp. Species 0.000 description 27
150000002500 ions Chemical class 0.000 description 26
235000015107 ale Nutrition 0.000 description 24
238000011160 research Methods 0.000 description 24
230000006907 apoptotic process Effects 0.000 description 23
210000000496 pancreas Anatomy 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 23
230000035899 viability Effects 0.000 description 20
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 19
102100037852 Insulin-like growth factor I Human genes 0.000 description 19
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 19
208000034615 apoptosis-related disease Diseases 0.000 description 19
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
241001465754 Metazoa Species 0.000 description 18
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 16
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 16
239000008103 glucose Substances 0.000 description 16
230000035882 stress Effects 0.000 description 16
238000012546 transfer Methods 0.000 description 16
206010028851 Necrosis Diseases 0.000 description 15
238000002955 isolation Methods 0.000 description 15
230000017074 necrotic cell death Effects 0.000 description 15
239000013598 vector Substances 0.000 description 15
238000001356 surgical procedure Methods 0.000 description 13
241000052343 Dares Species 0.000 description 12
230000029087 digestion Effects 0.000 description 12
230000006870 function Effects 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
238000001890 transfection Methods 0.000 description 12
241001136792 Alle Species 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
239000003102 growth factor Substances 0.000 description 11
239000013603 viral vector Substances 0.000 description 11
230000009471 action Effects 0.000 description 10
230000012010 growth Effects 0.000 description 10
230000009707 neogenesis Effects 0.000 description 10
238000005538 encapsulation Methods 0.000 description 9
238000001415 gene therapy Methods 0.000 description 9
101150093826 par1 gene Proteins 0.000 description 9
238000012360 testing method Methods 0.000 description 9
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
241000699800 Cricetinae Species 0.000 description 7
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000001605 fetal effect Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
241000272168 Laridae Species 0.000 description 6
238000007792 addition Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
238000013461 design Methods 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
238000011835 investigation Methods 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241000287531 Psittacidae Species 0.000 description 5
239000004098 Tetracycline Substances 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000034994 death Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
238000012423 maintenance Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
229960002180 tetracycline Drugs 0.000 description 5
229930101283 tetracycline Natural products 0.000 description 5
235000019364 tetracycline Nutrition 0.000 description 5
150000003522 tetracyclines Chemical class 0.000 description 5
238000011282 treatment Methods 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 4
102000011727 Caspases Human genes 0.000 description 4
108010076667 Caspases Proteins 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
241001633942 Dais Species 0.000 description 4
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 4
241000220317 Rosa Species 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
240000008042 Zea mays Species 0.000 description 4
210000000577 adipose tissue Anatomy 0.000 description 4
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
230000008901 benefit Effects 0.000 description 4
101150087654 chrnd gene Proteins 0.000 description 4
208000031513 cyst Diseases 0.000 description 4
230000007423 decrease Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
238000002513 implantation Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
230000001338 necrotic effect Effects 0.000 description 4
238000010606 normalization Methods 0.000 description 4
230000003076 paracrine Effects 0.000 description 4
235000015108 pies Nutrition 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
239000004071 soot Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
101150034533 ATIC gene Proteins 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
241000234282 Allium Species 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
101150064205 ESR1 gene Proteins 0.000 description 3
241001643597 Evas Species 0.000 description 3
206010020649 Hyperkeratosis Diseases 0.000 description 3
241000699729 Muridae Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
101150107341 RERE gene Proteins 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
101000921780 Solanum tuberosum Cysteine synthase Proteins 0.000 description 3
244000269722 Thea sinensis Species 0.000 description 3
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
235000002017 Zea mays subsp mays Nutrition 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000013019 agitation Methods 0.000 description 3
230000002424 anti-apoptotic effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
-1 aryl azide Chemical class 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
235000005822 corn Nutrition 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000013401 experimental design Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
125000001415 nervonoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
235000021251 pulses Nutrition 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
239000004576 sand Substances 0.000 description 3
210000000582 semen Anatomy 0.000 description 3
239000008279 sol Substances 0.000 description 3
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
230000008093 supporting effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001131 transforming effect Effects 0.000 description 3
NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 2
241001502050 Acis Species 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 2
241001116389 Aloe Species 0.000 description 2
241000272517 Anseriformes Species 0.000 description 2
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000282465 Canis Species 0.000 description 2
235000016795 Cola Nutrition 0.000 description 2
244000228088 Cola acuminata Species 0.000 description 2
235000011824 Cola pachycarpa Nutrition 0.000 description 2
241000143940 Colias Species 0.000 description 2
101710109085 Cysteine synthase, chloroplastic/chromoplastic Proteins 0.000 description 2
101710200331 Cytochrome b-245 chaperone 1 Proteins 0.000 description 2
102100037186 Cytochrome b-245 chaperone 1 Human genes 0.000 description 2
101710119396 Cytochrome b-245 chaperone 1 homolog Proteins 0.000 description 2
NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 2
241001505295 Eros Species 0.000 description 2
101150034814 F gene Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241001272567 Hominoidea Species 0.000 description 2
101100054972 Mus musculus Slc25a31 gene Proteins 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
241001134446 Niveas Species 0.000 description 2
235000014443 Pyrus communis Nutrition 0.000 description 2
241000612182 Rexea solandri Species 0.000 description 2
235000017276 Salvia Nutrition 0.000 description 2
241001072909 Salvia Species 0.000 description 2
241000607479 Yersinia pestis Species 0.000 description 2
NAXKFVIRJICPAO-LHNWDKRHSA-N [(1R,3S,4R,6R,7R,9S,10S,12R,13S,15S,16R,18S,19S,21S,22S,24S,25S,27S,28R,30R,31R,33S,34S,36R,37R,39R,40S,42R,44R,46S,48S,50R,52S,54S,56S)-46,48,50,52,54,56-hexakis(hydroxymethyl)-2,8,14,20,26,32,38,43,45,47,49,51,53,55-tetradecaoxa-5,11,17,23,29,35,41-heptathiapentadecacyclo[37.3.2.23,7.29,13.215,19.221,25.227,31.233,37.04,6.010,12.016,18.022,24.028,30.034,36.040,42]hexapentacontan-44-yl]methanol Chemical compound OC[C@H]1O[C@H]2O[C@H]3[C@H](CO)O[C@H](O[C@H]4[C@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]6[C@H](CO)O[C@H](O[C@H]7[C@H](CO)O[C@@H](O[C@H]8[C@H](CO)O[C@@H](O[C@@H]1[C@@H]1S[C@@H]21)[C@@H]1S[C@H]81)[C@H]1S[C@@H]71)[C@H]1S[C@H]61)[C@H]1S[C@@H]51)[C@H]1S[C@@H]41)[C@H]1S[C@H]31 NAXKFVIRJICPAO-LHNWDKRHSA-N 0.000 description 2
206010000496 acne Diseases 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
235000011399 aloe vera Nutrition 0.000 description 2
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000001270 angle-resolved resonant Auger electron spectroscopy Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
229940030850 avar Drugs 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000005611 electricity Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
229960004666 glucagon Drugs 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
210000004681 ovum Anatomy 0.000 description 2
210000000277 pancreatic duct Anatomy 0.000 description 2
210000004923 pancreatic tissue Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000010008 shearing Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000011269 tar Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
BFUTYTCDHCOXGG-UHFFFAOYSA-N 14,16,18,20,22,25,26,28,30-nonahydroxy-15,31-dimethyl-32-propan-2-yl-1-oxacyclodotriaconta-3,5,7,9,11-pentaen-2-one Chemical compound CC(C)C1OC(=O)C=CC=CC=CC=CC=CCC(O)C(C)C(O)CC(O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)C1C BFUTYTCDHCOXGG-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
NYPYHUZRZVSYKL-UHFFFAOYSA-N 2-azaniumyl-3-(4-hydroxy-3,5-diiodophenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 1
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
101150052147 ALLC gene Proteins 0.000 description 1
101150058502 Acaca gene Proteins 0.000 description 1
241000238876 Acari Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
241001103870 Adia Species 0.000 description 1
101100380303 Aeromonas salmonicida asaI gene Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
101100133992 Amycolatopsis sp Aaar gene Proteins 0.000 description 1
241000272522 Anas Species 0.000 description 1
240000000662 Anethum graveolens Species 0.000 description 1
241000252073 Anguilliformes Species 0.000 description 1
241001233887 Ania Species 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
241000237518 Arion Species 0.000 description 1
241000796533 Arna Species 0.000 description 1
101150036127 Arsg gene Proteins 0.000 description 1
241001076939 Artines Species 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000566113 Branta sandvicensis Species 0.000 description 1
240000002791 Brassica napus Species 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
101150110330 CRAT gene Proteins 0.000 description 1
101100445049 Caenorhabditis elegans elt-1 gene Proteins 0.000 description 1
101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
208000003643 Callosities Diseases 0.000 description 1
241000661938 Capsus Species 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
241000288673 Chiroptera Species 0.000 description 1
UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
241000581444 Clinidae Species 0.000 description 1
101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
241001137251 Corvidae Species 0.000 description 1
241000984642 Cura Species 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
244000000626 Daucus carota Species 0.000 description 1
235000002767 Daucus carota Nutrition 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
101150088702 Denr gene Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
MWRWFPQBGSZWNV-UHFFFAOYSA-N Dinitrosopentamethylenetetramine Chemical compound C1N2CN(N=O)CN1CN(N=O)C2 MWRWFPQBGSZWNV-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
241000241133 Earias Species 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241001184731 Eira Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
208000001836 Firesetting Behavior Diseases 0.000 description 1
241001123946 Gaga Species 0.000 description 1
244000287680 Garcinia dulcis Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000041633 Grewia tenax Species 0.000 description 1
235000005612 Grewia tenax Nutrition 0.000 description 1
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001078093 Homo sapiens Reticulocalbin-1 Proteins 0.000 description 1
101000596093 Homo sapiens Transcription initiation factor TFIID subunit 1 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
101150062179 II gene Proteins 0.000 description 1
241000093576 Icius Species 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
244000283207 Indigofera tinctoria Species 0.000 description 1
235000000177 Indigofera tinctoria Nutrition 0.000 description 1
101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
241001150538 Iria Species 0.000 description 1
241000023813 Isia Species 0.000 description 1
102100038356 Kallikrein-2 Human genes 0.000 description 1
244000074209 Leptadenia hastata Species 0.000 description 1
235000001008 Leptadenia hastata Nutrition 0.000 description 1
241001083878 Licania tomentosa Species 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000428198 Lutrinae Species 0.000 description 1
241000294754 Macroptilium atropurpureum Species 0.000 description 1
241001508691 Martes zibellina Species 0.000 description 1
108091026835 MicX sRNA Proteins 0.000 description 1
101150089916 Miox gene Proteins 0.000 description 1
244000294411 Mirabilis expansa Species 0.000 description 1
235000015429 Mirabilis expansa Nutrition 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100277637 Mus musculus Dffa gene Proteins 0.000 description 1
101100364971 Mus musculus Scai gene Proteins 0.000 description 1
101100256746 Mus musculus Setdb1 gene Proteins 0.000 description 1
240000009023 Myrrhis odorata Species 0.000 description 1
235000007265 Myrrhis odorata Nutrition 0.000 description 1
241000270276 Natrix Species 0.000 description 1
208000007256 Nevus Diseases 0.000 description 1
241001207999 Notaris Species 0.000 description 1
101150006181 OSTC gene Proteins 0.000 description 1
240000008881 Oenanthe javanica Species 0.000 description 1
241001024099 Olla Species 0.000 description 1
241000392035 Oreas Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
102000043299 Parathyroid hormone-related Human genes 0.000 description 1
101710123753 Parathyroid hormone-related protein Proteins 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241001387976 Pera Species 0.000 description 1
241001442654 Percnon planissimum Species 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
241001482237 Pica Species 0.000 description 1
235000012550 Pimpinella anisum Nutrition 0.000 description 1
240000007320 Pinus strobus Species 0.000 description 1
101150071557 Ppig gene Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
240000004350 Prunus spinosa Species 0.000 description 1
235000010829 Prunus spinosa Nutrition 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
240000001970 Raphanus sativus var. sativus Species 0.000 description 1
101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
102100025335 Reticulocalbin-1 Human genes 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000271569 Rhea Species 0.000 description 1
101150093156 Rras gene Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000801924 Sena Species 0.000 description 1
241001078998 Skimmia laureola Species 0.000 description 1
206010041235 Snoring Diseases 0.000 description 1
241001486863 Sprattus sprattus Species 0.000 description 1
101000720079 Stichodactyla helianthus DELTA-stichotoxin-She4a Proteins 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
241001415849 Strigiformes Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241001080024 Telles Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
101150045848 Tmbim6 gene Proteins 0.000 description 1
108091093130 Toxic Small RNA Proteins 0.000 description 1
102100035222 Transcription initiation factor TFIID subunit 1 Human genes 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
240000001085 Trapa natans Species 0.000 description 1
241001125843 Trichiuridae Species 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241000219094 Vitaceae Species 0.000 description 1
244000104547 Ziziphus oenoplia Species 0.000 description 1
235000005505 Ziziphus oenoplia Nutrition 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000032683 aging Effects 0.000 description 1
101150115889 al gene Proteins 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006851 antioxidant defense Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940059720 apra Drugs 0.000 description 1
108010035158 arginine esterase Proteins 0.000 description 1
101150050470 ase gene Proteins 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
101150090305 beg gene Proteins 0.000 description 1
XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
210000002236 cellular spheroid Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
239000001064 degrader Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
229940075911 depen Drugs 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
229940082150 encore Drugs 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
210000003020 exocrine pancreas Anatomy 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000019138 food restriction Nutrition 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
235000021021 grapes Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000004024 hepatic stellate cell Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
230000008004 immune attack Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
101150085091 lat-2 gene Proteins 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
235000013536 miso Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000014511 neuron projection development Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
230000001019 normoglycemic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
101150009564 oleC gene Proteins 0.000 description 1
229940044442 onfi Drugs 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940061319 ovide Drugs 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
NAHBVNMACPIHAH-HLICZWCASA-N p-ii Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC2=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)=O)C(C)C)C1=CC=CC=C1 NAHBVNMACPIHAH-HLICZWCASA-N 0.000 description 1
229930183263 paris Natural products 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000003415 peat Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
102000036213 phospholipid binding proteins Human genes 0.000 description 1
108091011000 phospholipid binding proteins Proteins 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
235000012830 plain croissants Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
235000012434 pretzels Nutrition 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000000746 purification Methods 0.000 description 1
206010037833 rales Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
101150101156 slc51a gene Proteins 0.000 description 1
239000000344 soap Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000001050 stape Anatomy 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
235000013547 stew Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
HLLICFJUWSZHRJ-UHFFFAOYSA-N tioxidazole Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)SC2=C1 HLLICFJUWSZHRJ-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
239000011800 void material Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Transplantation (AREA)
Oral & Maxillofacial Surgery (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Botany (AREA)
Urology & Nephrology (AREA)
Developmental Biology & Embryology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA 2437250 2003-08-14 2003-08-14 Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente Abandoned CA2437250A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2437250 CA2437250A1 (fr)	2003-08-14	2003-08-14	Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2437250 CA2437250A1 (fr)	2003-08-14	2003-08-14	Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente

Publications (1)

Publication Number	Publication Date
CA2437250A1 true CA2437250A1 (fr)	2005-02-14

Family

ID=34140448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2437250 Abandoned CA2437250A1 (fr)	2003-08-14	2003-08-14	Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente

Country Status (1)

Country	Link
CA (1)	CA2437250A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011011962A1 (fr) *	2009-07-31	2011-02-03	清华大学	Méthode de préparation de précurseurs complexes dorganes tissulaires multicouches
RU2429864C2 (ru) *	2005-10-21	2011-09-27	Ливинг Селл Продактс Пти Лимитед	Система инкапсуляции
US8202701B2 (en)	2004-10-08	2012-06-19	Georgia Tech Research Corporation	Microencapsulation of cells in hydrogels using electrostatic potentials
US11077289B2 (en)	2013-03-07	2021-08-03	Viacyte, Inc.	3-dimensional large capacity cell encapsulation device assembly
CN113730372A (zh) *	2021-10-15	2021-12-03	中国人民解放军陆军军医大学第二附属医院	一种神经干细胞磷脂膜微囊及其制备方法
CN114767837A (zh) *	2022-05-05	2022-07-22	合肥工业大学	一种口服胰岛素脂质体水凝胶及其应用
CN115737600A (zh) *	2022-11-25	2023-03-07	苏州大学	一种持续产氢生物微球及其制备方法与应用
CN119274722A (zh) *	2024-12-11	2025-01-07	青岛沙木新材料有限公司	单组分无溶剂刷涂型透明防水聚脲配方优化方法

2003
- 2003-08-14 CA CA 2437250 patent/CA2437250A1/fr not_active Abandoned

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8202701B2 (en)	2004-10-08	2012-06-19	Georgia Tech Research Corporation	Microencapsulation of cells in hydrogels using electrostatic potentials
RU2429864C2 (ru) *	2005-10-21	2011-09-27	Ливинг Селл Продактс Пти Лимитед	Система инкапсуляции
WO2011011962A1 (fr) *	2009-07-31	2011-02-03	清华大学	Méthode de préparation de précurseurs complexes dorganes tissulaires multicouches
US11077289B2 (en)	2013-03-07	2021-08-03	Viacyte, Inc.	3-dimensional large capacity cell encapsulation device assembly
US12296125B2 (en)	2013-03-07	2025-05-13	Viacyte, Inc.	3-dimensional large capacity cell encapsulation device assembly
CN113730372A (zh) *	2021-10-15	2021-12-03	中国人民解放军陆军军医大学第二附属医院	一种神经干细胞磷脂膜微囊及其制备方法
CN114767837A (zh) *	2022-05-05	2022-07-22	合肥工业大学	一种口服胰岛素脂质体水凝胶及其应用
CN115737600A (zh) *	2022-11-25	2023-03-07	苏州大学	一种持续产氢生物微球及其制备方法与应用
CN115737600B (zh) *	2022-11-25	2024-05-31	苏州大学	一种持续产氢生物微球及其制备方法与应用
CN119274722A (zh) *	2024-12-11	2025-01-07	青岛沙木新材料有限公司	单组分无溶剂刷涂型透明防水聚脲配方优化方法

Legal Events

Date	Code	Title	Description
2005-11-17	FZDE	Dead

Publication	Publication Date	Title
Grattoni et al.	2025	Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead
O'Shea et al.	1986	Encapsulation of rat islets of Langerhans prolongs xenograft survival in diabetic mice
Pareta et al.	2014	Long-term function of islets encapsulated in a redesigned alginate microcapsule construct in omentum pouches of immune-competent diabetic rats
Herrera et al.	2004	A novel pathway of alloantigen presentation by dendritic cells
Scott et al.	2004	Beyond the red cell: pegylation of other blood cells and tissues
US20070299508A1 (en)	2007-12-27	Vascularized tissue graft
Ramzy et al.	2023	A century-long journey from the discovery of insulin to the implantation of stem cell–derived islets
Rajendran Nair et al.	2021	Long-term transplant effects of iPSC-RPE monolayer in immunodeficient RCS rats
CN109069605A (zh)	2018-12-21	新免疫原性CD1d结合肽
CA2437250A1 (fr)	2005-02-14	Microencapsulation de cellules vivantes dans des membranes d'alginate-poly-l-lysine-alginate a reticulation covalente
Jauregui et al.	1996	Use of mammalian liver cells for artificial liver support
Mooranian et al.	2021	Artificial cell encapsulation for biomaterials and tissue bio-nanoengineering: history, achievements, limitations, and future work for potential clinical applications and transplantation
Miglietta et al.	2021	Hypoparathyroidism: state of the art on cell and tissue therapies
Melgar-Lesmes et al.	2017	Implantation of healthy matrix-embedded endothelial cells rescues dysfunctional endothelium and ischaemic tissue in liver engraftment
Willing et al.	1998	Sertoli cell transplants: their use in the treatment of neurodegenerative disease
EP0577719A1 (fr)	1994-01-12	Dispositif de perfusion pancreatique artificiel pourvu d'une matrice de reensemencement.
HUE025872T2 (en)	2016-05-30	Primary, cultured adipocytes for gene therapy
Mu-U-Min et al.	2025	Immune Evasion in Stem Cell-Based Diabetes Therapy—Current Strategies and Their Application in Clinical Trials
Opara et al.	2024	Challenges and perspectives for future considerations in the bioengineering of a bioartificial pancreas
NO320334B1 (no)	2005-11-21	Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller.
EP0955948B1 (fr)	2005-06-15	Induction d'une tolerance immunologique
ES2299417T3 (es)	2008-06-01	Metodo para producir preparaciones de celulas endocrinas pancreaticas madura e inmaduras, preparacion de las celulas y su utilizacion para el tratamiento de la diabetes mellitus.
CA2179341A1 (fr)	1997-10-13	Methodes pour isoler, enrichir des cultures cellulaires, et accelerer leur maturation
CN101848746A (zh)	2010-09-29	勃起机能的恢复方法
ES2379008T3 (es)	2012-04-19	Macroperlas que contienen células secretoras que comprenden agarosa Seakem Gold, y sus usos